HPS Pharmacies wish to give notice that Bayer Australia are experiencing a supply interruption for nimodipine as follows:
Nimotop® 30mg Tablets
The supply interruption is due to a manufacturing issue affecting the tablet formulation of nimodipine. The intravenous formulation of nimodipine is not affected and continues to be available. Normal supplies of nimodipine tablets are expected to resume in April 2018.
While wholesaler stocks of nimodipine tablets are exhausted, HPS Pharmacies can source a limited supply of internationally registered nimodipine tablets for the benefit of our clients. Access will be under the Special Access Scheme for immediate supply to seriously ill patients, pending completion and forwarding of the Category A SAS form by the medical practitioner. Non-urgent supplies require completion of a Category B form, and approval by the TGA prior to use.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Bayer Australia on 1800 039 076.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.